Thien-Kim Co, DO
Internal Medicine · Los Angeles, CANPI 1033732953
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Aurinia Pharma U.S., Inc. at 28.5% of the total.
Across 44 payments — averaging $28.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurinia Pharma U.S., Inc.$351
- Bayer$212
- Merck$137
- Vertex$125
- Paratek Pharmaceuticals, Inc.$74
- AstraZeneca$63
- plus $270 from 7 others
What the payments were for
- Food & beverage$1,232100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurinia Pharma U.S., Inc. | 12 | $351 |
| Bayer | 8 | $212 |
| Merck | 7 | $137 |
| Vertex | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 4 | $74 |
| AstraZeneca | 2 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Ardelyx, Inc. | 2 | $53 |
| OPKO Pharmaceuticals, LLC | 2 | $44 |
| Veloxis Pharmaceuticals, Inc. | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Calliditas Therapeutics US Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
How this compares
$1,232 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 12 | $624 |
| Calcitriol | 11 | $229 |
| Hydralazine Hcl | 11 | $145 |
| Metformin Hcl | 28 | $131 |
| Pravastatin Sodium | 34 | $123 |
| Losartan Potassium | 18 | $110 |
| Tamsulosin Hcl | 15 | $104 |
| Amlodipine Besylate | 11 | $69 |
| Allopurinol | 15 | $57 |
| Furosemide | 14 | $36 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.